

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/523,478	02/04/2005		Dramane I. Laine	P51368	3653	
20462	7590	12/09/2005		EXAMINER		
		CHAM CORPOR	СЕМВЕН, S	GEMBEH, SHIRLEY V		
P. O. BOX 1		LECTUAL PROPE	ART UNIT	PAPER NUMBER		
KING OF PI	RUSSIA,	PA 19406-0939	1614			

DATE MAILED: 12/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

 		,	Application No.	Applicant(s)					
Office Action Summary			10/523,478	LAINE ET AI	L.				
			Examiner	Art Unit					
			Shirley V. Gembeh	1614					
Period fo	The MAILING DATE of this communi or Reply	ication appea	ars on the cover sheet w	ith the corresponden	ce address				
WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MANSIONS OF THE MANSIO	AILING DAT of 37 CFR 1.136(unication. tutory period will will, by statute, ca	E OF THIS COMMUNI (a). In no event, however, may a apply and will expire SIX (6) MORAUSE the application to become A	CATION. reply be timely filed NTHS from the mailing date o BANDONED (35 U.S.C. § 13	f this communication.				
Status									
1)□	Responsive to communication(s) file	d on .							
· <u></u>			ction is non-final.						
′=	Since this application is in condition to	<i>,</i> —		ters, prosecution as	to the merits is				
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	4)⊠ Claim(s) <u>1-9</u> is/are pending in the application.								
•	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	Claim(s) is/are allowed.								
6)	Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8)🖂	Claim(s) <u>1-9</u> are subject to restriction	and/or elec	ction requirement.						
Applicati	on Papers								
9)	The specification is objected to by the	e Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of	of the priority	y documents have beer	received in this Nati	ional Stage				
	application from the Internation	•	* **						
* S	See the attached detailed Office action	n for a list of	the certified copies not	received.					
Attachmen	t(s)								
1) Notic	e of References Cited (PTO-892)			Summary (PTO-413)					
	e of Draftsperson's Patent Drawing Review (P			(s)/Mail Date Informal Patent Application	n (PTO-152)				
	nation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date	P1U/SB/U8)	6) Other:						

Application/Control Number: 10/523,478

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3 and 7 are drawn to a compound composition of formula 1

Group II, claim(s) 4-6, are drawn to a method of treating a disease or disorder selected chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis, irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal convulsions or hyperanakinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature; urinary-tract disorders accompanying micturition disorders, neurogenic pollakisuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, and motion sickness.

from

Group III, claim(s) 8-9, are drawn to a metering valve device for intranasal delivery.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or

Application/Control Number: 10/523,478

Art Unit: 1614

corresponding special technical features for the following reasons: The compound is already known in the art (see reference WO 0064864 A1 pages 10 +).

This application contains claims directed to more than one species of the formula

1. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Specifically, applicant is required to define each of R¹, R², R³ and n and any additional variables as required for a particular species.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a claim to formula 1, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the

Art Unit: 1614

case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Election/Restrictions Proper

MPEP §809.02(d) states "[w]here only generic claims are presented, no restriction can be required except in those applications where the claim(s) recite such a multiplicity of species of formula 1 that an unduly extensive and burdensome search is necessary.". Here, the claims recited such a multiplicity of species that an unduly extensive and burdensome search would be necessary if all of the claimed species were to be examined simultaneously.

The present claims are directed to a method of treating respiratory complaints. Present claim 1 for example provides a variety of possibilities for R¹, R², R³ and n. For hypothetical exemplification purposes only, if each of the variables above were each limited to 10 possible moieties there would be 10⁴ possible species of compounds to be searched.

Further, as shown by the following classifications, a majority of the combinations encompassed by the present claims has acquired a separate status in the art. For example, if the method is directed towards the treatment of asthma will fall into class 514 subclass 826.

Art Unit: 1614

Notwithstanding that the classification of some of the active agents is co-extensive, all of the claimed compounds are patently distinct and fully capable of supporting separate patents.

For the above reasons, an election of a single disclosed species for examination purposes is deemed necessary and proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christophossolu

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

SVG 12/01/05